ABSTRACT
Objective: To identify whether the drug purchases made by the Health Consortia were more efficient, in economic terms, than the purchases made individually by the Municipal Institutions, for the years 2017 and 2018. Methods: Descriptive analysis of the sample, using the trend measures central, economic analysis and calculation of the economic percentage. Results: The values obtained showed efficiency in consortium purchases, reflected in the greater quantity acquired and the lower price practiced, for most of the items analyzed in the reference period. Conclusions: Purchases by Health Consortia provided more savings compared to purchases made by Municipal Institutions, proving to be an option to obtain economic resources for health.
ABSTRACT
Objetivo: Identificar se as aquisições de medicamentos realizadas pelos Consórcios de Saúde foram mais eficientes, em termos econômicos, que as compras realizadas individualmente pelas Instituições Municipais, para os anos de 2017 e 2018. Métodos: Análise descritiva da amostra, empregando as medidas de tendência central, análise econômica e cálculo do percentual econômico. Resultados: Os valores obtidos mostraram eficiência nas compras dos consórcios, refletidos na maior quantidade adquirida e no menor preço praticado, para a maioria dos itens analisados no período de referência. Conclusão: As compras pelos Consórcios de Saúde proporcionaram mais economia em comparação com as compras realizadas pelas Instituições Municipais, mostrando-se como uma opção para obter economicidade dos recursos destinados à saúde.
Objective: To identify whether the drug purchases made by the Health Consortia were more efficient, in economic terms, than the purchases made individually by the Municipal Institutions, for the years 2017 and 2018. Methods: Descriptive analysis of the sample, using the trend measures central, economic analysis and calculation of the economic percentage. Results: The values obtained showed efficiency in consortium purchases, reflected in the greater quantity acquired and the lower price practiced, for most of the items analyzed in the reference period. Conclusion: Purchases by Health Consortia provided more savings compared to purchases made by Municipal Institutions, proving to be an option to obtain economic resources for health.
Subject(s)
Drug Price , Unified Health System , Economics, Pharmaceutical , Health Price BankABSTRACT
Optimizing the drug price management mechanism and improving the availability and affordability of drugs are important in deepening the medical and health reform. The price of drugs in the United States has always been higher than the world average. The price of drugs, the total expenditure on drugs and the personal burden of patients have shown an increasing trend. By exploring the causes of high drug prices in the United States, the author found that there were four main reasons for the current situation of drug prices in the United States, including the interests of enterprises, the limited competition mechanism of the US drug market, relatively insufficient market bargaining power of the US payers, and opaque mechanism of price formation.Firstly, pharmaceutical companies try to achieve their interests by raising drug prices. Secondly, the price formation mechanism of the United States drug market is affected by the price strategy of pharmaceutical companies, and government policies also indirectly affect the role of the market. Thirdly, the payers in the United States are relatively scattered, so that the market bargaining power is relatively insufficient.Fourthly, due to the numerous drug circulation links and stakeholders, the drug price formation mechanism is opaque and lacks supervision. Therefore, when strengthening drug price management in China, we should build a coordination mechanism between the government and the market on the basis of the existing basic economic system and drug management mechanism, establish the strategic purchase and negotiation position of medical insurance for drugs, enhance the transparency of drug circulation and trading, and establish a scientific pricing system. It is also important to promote drug innovation and ensure drug quality.
ABSTRACT
It put forward the mechanism of drug pricing and price-adjusting based on classification of drug value.It can set different prices according to different value The higher the value is,the higher the price will be.It could embody the principle of good quality,good price so as to and ensure the unity of price and value.
ABSTRACT
OBJECTIVE:To discuss the causes and related treatment strategies of artificially high drug prices. METHODS:The causes of artificially high drug prices were analyzed from drug price formation,distribution and trading,drug use in medical institutions and other aspects,in order to sort out the overall plan and treatment strategies of artificially high drug prices. RESULTS& CONCLUSIONS:Artificially high drug prices are resulted from not sound pricing mechanism,numerous circulation links,im-perfect procurement system,“drug maintaining medicine”mechanism of medical institutions and other factors. It is suggested to solve artificially high drug prices from perfecting drug market price formation mechanism,promoting circulation reform,improving centralized purchasing trading mechanism;at the same time,accelerating the reform of medicare payment system,deepening the re-form of public medical institutions operating mechanism and perfecting supervision laws and regulations so as to gradually improve the drug price administration system and realize reasonable drug pricing.
ABSTRACT
Objetivo: evaluar los cambios en la demanda de servicios en salud, luego de la actualización del plan de beneficios de Colombia, entre los años 2010 y 2012. Métodos: estudio tipo descriptivo y explicativo, donde se evalúa el uso de tecnologías sanitarias antes y después de la actualización del Plan Obligatorio de Salud. Se tomaron las dispensaciones de medicamentos entre el 2010 y el 2012 del Sistema de Información de Precios de Medicamentos. Para valorar los cambios se construyó una escala de valoración de cambios porcentuales. Resultados: se evidenciaron cambios en el comportamiento de la demanda de servicios. Como se esperaba, la actualización del Plan de Beneficios representa para los pacientes mayor acceso a las nuevas tecnologías, medido a través del mayor uso de tecnologías nuevas. Conclusión: la actualización del plan de beneficios mejoró el acceso de los pacientes a una gran parte de los servicios de salud.
Objective: Assessing the changes in the demand of health services after the update of the benefit plan in Colombia, during 2010 and 2012. Methods: Descriptive and Explanatory type study, where the use of healthcare technologies before and after the update of the Compulsory Health Plan is assessed. We took the drug dispensations between 2010 and 2012 from the Drug Price Information System. To assess the changes, we made an evaluation scale of percentage changes. Results: We found evidence of changes in the behavior of the demand of services. As expected, the update of the Benefits Plan represents greater access to new technologies, measured through a greater use of new technologies. Conclusion: The update of the Benefits Plan improved access for patients to a large part of the health services.
Objetivo: avaliar as mudancas na demanda de servicos em saúde, após atualizacao do plano de beneficios da Colombia, entre os anos 2010 e 2012. Métodos: estudo tipo descritivo e explicativo, onde avalia-se o uso de tecnologias sanitarias antes e depois da atualizacao do Plano Obrigatório de Saúde. Tomaram-se as dispensares de medicamentos entre o 2010 e 2012 do Sistema de Informacao de Precos de Medicamentos. Para avaliar as mudancas foi construída uma escala de valoracao de mudancas porcentuais. Resultados: evidenciaram-se mudancas no comportamento da demanda de servicos. Como esperado, a atualizacao do Plano de Beneficios representa para os pacientes maior acesso as novas tecnologias, medido a través do maior uso de tecnologia nova. Conclusao: a atualizacao do plano de beneficios melhorou o acesso dos pacientes a uma grande parte dos servicos de saúde.
ABSTRACT
<b>Objective: </b>From the viewpoint of drug cost reduction, many generic drugs have appeared in the eye drops market. Although the price of eye drops is defined on a per bottle (or per mL) basis, the difference in the total number of drops per bottle between the original drug and its generic drug may alter the drug cost reduction effect greatly. Moreover, the difference in the total number of drops per bottle may also affect the number of pharmacy visits made by a patient in one year.<br><b>Methods: </b>The total number of drops per bottle of an original drug and a generic drug was computed, and the influence of the number of drops on the drug cost reduction effect, including drug cost, was evaluated.<br><b>Results: </b>Distinct differences in the volume per drop and the total number of drops per bottle were observed between the original drug and its generic drug, and those differences were found to clearly influence the drug cost reduction effect. Moreover, in a survey of patients who shifted to generic eye drops, there were some patients who returned to the original eye drops because they could not apply the generic eye drops with ease or their eyes started to smart after using the generic eye drops.<br><b>Conclusion: </b>This study revealed the need to take into consideration patient’s ease of use and the drug cost reduction effect, in the selection of eye drops.
ABSTRACT
OBJECTIVE:To investigate the procurability and prices of essential medicines in Hubei Xiaogan rural area.METHODS:According to the standard methodology for the investigation of drug prices recommended by the World Health Organization and European Health Action International organization,a survey on the procurability and prices of essential medicines was conducted in 4 hospitals and 3 drugstores in Hubei Xiaogan rural area.RESULTS:The procurability of essential medicines in both hospitals and drugstores was low.The prices of drugs were lower in drugstores than in hospitals.As compared with the international reference prices,the drug prices in drugstores were lower while those in hospitals were higher.The markup ratio in one hospital was far above 15.0%,while those in the other two hospitals were all within 15.0%.CONCLUSION:The procurability of essential medicines in Hubei Xiaogan rural area remains to be increased,and there is space for the reduction of drug prices.
ABSTRACT
OBJECTEVE:To probe into the difference of drug prices between used in hospital and retailed in market.METHODS:Analysis the different reasons of drug price from drug quality assurance system,pharmaceutical care,drug using structure system and function mechanism.RESULTS&CONCLUSION:It's rational that the drug prices used in hospital high_ er than in retailed market.It's pratical and realistic attitude to the fact that the same drug has different prices in the medical market.